Amundi Buys 183 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Amundi increased its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,143 shares of the company’s stock after acquiring an additional 183 shares during the period. Amundi’s holdings in PROCEPT BioRobotics were worth $1,742,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PRCT. Lord Abbett & CO. LLC lifted its position in PROCEPT BioRobotics by 45.3% in the third quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company’s stock valued at $59,974,000 after purchasing an additional 233,430 shares during the last quarter. Perpetual Ltd bought a new stake in PROCEPT BioRobotics during the 4th quarter valued at $66,972,000. Penserra Capital Management LLC purchased a new stake in PROCEPT BioRobotics during the 3rd quarter valued at $2,308,000. Oak Ridge Investments LLC grew its holdings in PROCEPT BioRobotics by 24.0% in the 4th quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company’s stock worth $2,420,000 after acquiring an additional 5,817 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of PROCEPT BioRobotics by 295.8% in the fourth quarter. SG Americas Securities LLC now owns 6,598 shares of the company’s stock valued at $531,000 after acquiring an additional 4,931 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Stock Up 2.4 %

PRCT stock opened at $59.03 on Tuesday. PROCEPT BioRobotics Co. has a fifty-two week low of $45.56 and a fifty-two week high of $103.81. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of -30.27 and a beta of 1.05. The business’s 50 day moving average price is $70.07 and its two-hundred day moving average price is $79.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PRCT has been the subject of a number of analyst reports. Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Truist Financial reiterated a “buy” rating and issued a $90.00 price objective (down from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Finally, Morgan Stanley decreased their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, PROCEPT BioRobotics currently has an average rating of “Moderate Buy” and an average price target of $94.29.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).